– IRELAND, Belfast – Fusion Antibodies plc (LON: FAB), specialists in pre-clinical antibody discovery, engineering, and supply, today announced the appointment of Dr. Matthew Baker (Ph.D.) to its Board as a Non-Executive Director with effect from 1 March 2022, bringing detailed immunology, antibody, and virus-based mammalian display knowledge to the Board as well as industry and services market insight.
“I am very pleased to welcome Matthew to the Board of Fusion Antibodies. His extensive experience of the antibody services business, both from a technical and commercial perspective, will be a great benefit the Company going forward. This will be further strengthened by his continuing role on our Scientific Advisory Panel,” said Board Chairman, Simon Douglas.
The Company also announces that Dr. Alan Mawson will be stepping down as a Non-Executive Director of the Company with effect from 31 March 2022.
About Dr. Matthew Baker
Dr. Baker is currently a member of the Scientific Advisory Panel, details of which were announced on 14 January 2022. He has more than 20 years of experience developing biologics in biotech and pharma companies and is a research expert in B and T-cell immunology, including drug immunogenicity. He co-founded Antitope Ltd, a service-based company focused on using proprietary technologies to humanize antibodies, and was the CSO of Abzena plc, an antibody services company, until 2016. He previously held a Non-Executive Director role at Oxford Genetics Ltd and is currently the CEO of NeoPhore Limited, a private company focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system.
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification, and sequencing, antibody humanization using Fusion’s proprietary CDRxTM platform, and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and completed over 200 humanization projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client’s vision is central to how we work in combining the latest technological advances with cutting-edge science. In this work, our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation to ensure the best molecule goes to the clinic. Fusion Antibodies’ growth strategy is based on enabling Pharma and Biotech companies to get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion’s use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,
Fusion Antibodies’ emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.
For more information: https://www.fusionantibodies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
